
Andrew H Talal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5060334/publications.pdf Version: 2024-02-01



ΔΝΟΡΕΊΝ Η ΤΛΙΛΙ

#	Article	IF	CITATIONS
1	Hepatitis C virus infection in USA: an estimate of true prevalence. Liver International, 2011, 31, 1090-1101.	1.9	355
2	Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology, 2008, 48, 1440-1450.	3.6	194
3	Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood, 2005, 106, 1175-1182.	0.6	168
4	Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection. Gastroenterology, 2012, 143, 1244-1252.e12.	0.6	142
5	Pharmacodynamics of PEG-IFN \hat{I}_{\pm} differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology, 2006, 43, 943-953.	3.6	81
6	Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World Journal of Gastroenterology, 2013, 19, 7846.	1.4	74
7	Interferon Î ³ -Inducible Protein 10. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 262-268.	0.9	53
8	Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus Management in Opioid Use Disorder Patients on Methadone. Clinical Infectious Diseases, 2019, 69, 323-331.	2.9	50
9	Hepatitis C Virus–Related Knowledge and Willingness to Receive Treatment Among Patients on Methadone Maintenance. Journal of Addiction Medicine, 2014, 8, 249-257.	1.4	37
10	Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. Journal of Hepatology, 2011, 55, 545-553.	1.8	34
11	A framework for patient-centered telemedicine: Application and lessons learned from vulnerable populations. Journal of Biomedical Informatics, 2020, 112, 103622.	2.5	33
12	Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. Addictive Disorders and Their Treatment, 2017, 16, S1-S23.	0.5	29
13	Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment. Clinical Pharmacology in Drug Development, 2017, 6, 206-212.	0.8	29
14	Virus Dynamics and Immune Responses During Treatment in Patients Coinfected With Hepatitis C and HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 103-113.	0.9	26
15	Diagnostic accuracy of intracellular uptake rates calculated using dynamic Gdâ€EOBâ€DTPAâ€enhanced MRI for hepatic fibrosis stage. Journal of Magnetic Resonance Imaging, 2017, 45, 1177-1185.	1.9	25
16	Patient Reaction to Telemedicine for Clinical Management of Hepatitis C Virus Integrated into an Opioid Treatment Program. Telemedicine Journal and E-Health, 2019, 25, 791-801.	1.6	25
17	Telaprevirâ€based treatment effects on hepatitis C virus in liver and blood. Hepatology, 2014, 60, 1826-1837.	3.6	22
18	A Hepatitis C Viral Kinetic Model that Allows for Time-Varying Drug Effectiveness. Antiviral Therapy, 2008, 13, 919-926.	0.6	22

ANDREW H TALAL

#	Article	IF	CITATIONS
19	Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. Journal of Viral Hepatitis, 2019, 26, 951-960.	1.0	21
20	Hepatitis C virus knowledge improves hepatitis C virus screening practices among primary care physicians. World Journal of Hepatology, 2018, 10, 319-328.	0.8	18
21	Genetic Variation at IFNL4 Influences Extrahepatic Interferon-Stimulated Gene Expression in Chronic HCV Patients. Journal of Infectious Diseases, 2018, 217, 650-655.	1.9	17
22	Noninjection drug use: an underâ€appreciated risk factor for hepatitis C virus transmission. Liver International, 2008, 28, 757-760.	1.9	16
23	Improvements in HCV-related Knowledge Among Substance Users on Opioid Agonist Therapy After an Educational Intervention. Journal of Addiction Medicine, 2016, 10, 104-109.	1.4	16
24	Toward Optimal Control of Hepatitis C Virus Infection in Persons With Substance Use Disorders. Annals of Internal Medicine, 2017, 166, 897.	2.0	16
25	Liver-to-Plasma Vaniprevir (MK-7009) Concentration Ratios in HCV-Infected Patients. Antiviral Therapy, 2015, 20, 843-848.	0.6	14
26	Ultra-performance liquid chromatography tandem mass spectrometry for determination of Direct Acting Antiviral drugs in human liver fine needle aspirates. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1052, 103-109.	1.2	14
27	Influence of social determinants of health and substance use characteristics on persons who use drugs pursuit of care for hepatitis C virus infection. Journal of Substance Abuse Treatment, 2019, 102, 33-39.	1.5	14
28	Toward precision prescribing for methadone: Determinants of methadone deposition. PLoS ONE, 2020, 15, e0231467.	1.1	14
29	IFN-α-Induced Downregulation of miR-221 in Dendritic Cells: Implications for HCV Pathogenesis and Treatment. Journal of Interferon and Cytokine Research, 2015, 35, 698-709.	0.5	12
30	Development and validation of a UPLC–MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver. Bioanalysis, 2016, 8, 1353-1363.	0.6	12
31	Opportunistic infections in HIV-infected individuals: hepatitis C virus. Lancet, The, 2002, 360, 584-586.	6.3	10
32	Randomized Trial Comparing Dose Reduction and Growth Factor Supplementation for Management of Hematological Side Effects in HIV/Hepatitis C Virus Patients Receiving Pegylated-Interferon and Ribavirin. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 261-268.	0.9	10
33	Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment. Journal of Substance Abuse Treatment, 2013, 44, 115-119.	1.5	10
34	Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus–Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin. Journal of Infectious Diseases, 2015, 211, 1795-1799.	1.9	10
35	Dendritic Cells in HIV-1 and HCV Infection: Can They Help Win the Battle?. Virology: Research and Treatment, 2013, 4, VRT.S11046.	3.5	8
36	Hepatitis C virus core antigen: A potential alternative to HCV RNA testing among persons with substance use disorders. Journal of Substance Abuse Treatment, 2017, 78, 37-42.	1.5	8

ANDREW H TALAL

#	Article	IF	CITATIONS
37	Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy. Journal of Infectious Diseases, 2020, 222, 601-610.	1.9	7
38	Patient-centered HCV care via telemedicine for individuals on medication for opioid use disorder: Telemedicine for Evaluation, Adherence and Medication for Hepatitis C (TEAM-C). Contemporary Clinical Trials, 2022, 112, 106632.	0.8	7
39	Improvements in Quality of Life: A New Indication for Treating Hepatitis C Virus Infection in Persons With Substance Use Disorders. Journal of Infectious Diseases, 2018, 217, 1020-1023.	1.9	6
40	Assessing routes of hepatitis C transmission in HIV-infected men who have sex with men using single genome sequencing. PLoS ONE, 2020, 15, e0235237.	1.1	6
41	The HCV and HIV coinfected patient: What have we learned about pathophysiology?. Current Gastroenterology Reports, 2002, 4, 15-22.	1.1	5
42	Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage. Journal of Infectious Diseases, 2018, 217, 474-482.	1.9	5
43	Facilitating engagement of persons with opioid use disorder in treatment for hepatitis C virus infection via telemedicine: Stories of onsite case managers. Journal of Substance Abuse Treatment, 2021, 127, 108421.	1.5	5
44	Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	4
45	Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology. Clinical Pharmacology in Drug Development, 2017, 6, 169-175.	0.8	2
46	Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals. Journal of Clinical & Cellular Immunology, 2014, 05, .	1.5	1
47	Drug–Drug Interactions and Diagnostics for Drug Users With HIV and HIV/HCV Coinfections: Introduction. Clinical Pharmacology in Drug Development, 2017, 6, 108-117.	0.8	0
48	Fineâ€Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection. Clinical Pharmacology and Therapeutics, 2020, 107, 1325-1333.	2.3	0
49	Age―and risk factor–based serologic screening for Hepatitis C virus among an Urban, highâ€risk population. Journal of Viral Hepatitis, 2020, 27, 1369-1387.	1.0	0
50	Hepatitis C Virus Treatment Delivered via Telemedicine to Persons With Opioid Use Disorder. JAMA Internal Medicine, 0, , .	2.6	0